Menu

Springer Nature Blocks Access to Sensitive Articles Within China

The world’s largest publisher yields to censorship policies of the world’s largest country.

Nov 1, 2017
The Scientist Staff

ISTOCKThe academic publisher Springer Nature has blocked access within China to about 1,000 articles on topics such as the status of Tibet and the 1989 Tiananmen Square protests, the Financial Times reported yesterday (October 31). Although the censorship affects less than 1 percent of the publisher’s material, which can still be read outside China, it is an illustration of how much clout the country’s central government can hold over international companies.

“It’s a symbol of how unprepared we are in the west for China’s influence expanding outwards,” Jonathan Sullivan of the University of Nottingham’s China Policy Institute, tells the Financial Times. “It’s about how we perceive our relationship with China and how much we value principles versus the instrumental benefits of pleasing the authorities in China.”

In a statement to the Associated Press, Springer Nature says that if it had not selectively blocked access to its politically sensitive articles, access to its entire SpringerLink website could have been blocked by China’s “Great Firewall.” If that were to happen, the publisher would join a long list of major international sites that are blocked. Google, for example, was blocked after announcing in 2010 that it would no longer censor its search results within China.

Reuters reports that at least one academic publisher has responded to pressure to move away from censorship: Cambridge University Press recently reversed a decision to remove about 300 articles from its Chinese site, after it was criticized by academics “as an affront to academic freedom.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.